Schedule 13D ownership disclosure

ADAPTIMMUNE THERAPEUTICS PLC

Ordinary Shares, (pound).001 par value per share · CUSIP: 00653A107

Event date: 2025-08-15

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • New Enterprise Associates 14, L.P.Reported CIK 0001544328

    Shares: 4.00 · Class: 0%

  • NEA Partners 14, L.P.Reported CIK 0001551531

    Shares: 4.00 · Class: 0%

  • NEA 14 GP, LTDReported CIK 0001551532

    Shares: 4.00 · Class: 0%

  • New Enterprise Associates 16, L.P.Reported CIK 0001694560

    Shares: 4.00 · Class: 0%

  • NEA Partners 16, L.P.Reported CIK 0001712881

    Shares: 4.00 · Class: 0%

  • NEA 16 GP, LLCReported CIK 0001712882

    Shares: 4.00 · Class: 0%

  • Forest BaskettReported CIK 0001277631

    Shares: 4.00 · Class: 0%

  • Anthony A. Florence, Jr.Reported CIK 0001559827

    Shares: 4.00 · Class: 0%

  • Patrick J. KerinsReported CIK 0001235112

    Shares: 4.00 · Class: 0%

  • Mohamad H. MakhzoumiReported CIK 0001630226

    Shares: 4.00 · Class: 0%

  • Scott D. SandellReported CIK 0001237289

    Shares: 4.00 · Class: 0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001072613-25-000670
Form type
SCHEDULE 13D/A
Filer
Adaptimmune Therapeutics PLC
CIK
CIK 1621227
Filed
Aug 19, 2025
Reporting period
Aug 15, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub